Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11058440 | 0.77 | CYP3A4 (0.43) | MEN1KMT2ACHEK1 | |
| SCHEMBL5422243 | 0.74 | SLC6A4 (0.42) | MEN1KMT2ACHEK1 | |
| SCHEMBL6985196 | 0.71 | IDO1 (0.50) | MEN1KMT2ACHEK1 | |
| SCHEMBL1343862 | 0.69 | TAAR1 (0.54) | MEN1KMT2A | |
| SCHEMBL28630653 | 0.66 | IDO1 (0.50) | MEN1KMT2ACHEK1 | |
| SCHEMBL17954417 | 0.66 | TRPV4 (0.52) | — | |
| SCHEMBL25370453 | 0.66 | ALDH1A1 (0.52) | — | |
| SCHEMBL25369768 | 0.66 | CYP2A6 (0.35) | — | |
| SCHEMBL663110 | 0.64 | MEN1 (0.48) | MEN1KMT2A | |
| SCHEMBL24300648 | 0.64 | MEN1 (0.50) | MEN1KMT2ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146041-B1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-6420413-B2 | 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | LES LABORATOIRES SERVIER (FR) | 2002-02-14 | — | — | US | disclosed |
| EP-1146041-A1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | HSD3B2, HSD3B1, NR1H3 | MEN1 2535/4885KMT2A 2843/4885CHEK1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.